Use of nalmefene in non-alcoholic steatohepatitis
The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and/or ASH.
1. A method of treating, NASH, which comprises administering to a human or animal in need thereof a therapeutic amount of a compound of the formula (I), wherein:
A is OH or OCH3, R is H, CH3, or cyclopropylmethyl;
X is the oxygen atom, Y is CH2 or oxygen, Z is H or OH, said compounds being administered as a racemic mixture or as enantiomers, diastereoisomers, or pharmaceutically acceptable salts.
2. The method of claim 1 , wherein the compound of Formula (I) has one of the following structures:
3. The method of claim 1 , wherein the compound of Formula (I) has one of the following structures:
4. A method as claimed in claim 1 , wherein said compound is Compound A (nalmefene).
5. A method as claimed in claim 1 , wherein said compound is Compound B (naltrexone).
6. A method of treating NAFLD, which comprises administering to a human or animal in need thereof a therapeutic amount of a compound of the formula (I), wherein:
A is OH or OCH3, R is H, CH3, or cyclopropylmethy;
X is the oxygen atom, Y is CH2 or oxygen, Z is H or OH, said compounds being administered as a racemic mixture or as enantiomers, diastereoisomers, or pharmaceutically acceptable salts.
7. A method of treating-ASH, which comprises administering to a human or animal in need thereof a therapeutic amount of a compound of the formula (I), wherein:
A is OH or OCH3, R is H, CH3, or cyclopropylmethyl;
X is the oxygen atom, Y is CH2 or oxygen, Z is H or OH, said compounds being administered as a racemic mixture or as enantiomers, diastereoisomers, or pharmaceutically acceptable salts.
8. The method of claim 1 , wherein the compound is administered orally.
9. The method of claim 1 , wherein the compound is administered parenterally.
10. A method as claimed in claim 1 wherein said compound is administered in a daily dose of from 1 mg to 100 mg.
11. The method of claim 6 , wherein the compound of Formula (I) has one of the following structures:
12. The method of claim 6 , wherein the compound of Formula (I) has one of the following structures:
13. A method as claimed in claim 6 , wherein said compound is Compound A (nalmefene).
14. A method as claimed in claim 6 , wherein said compound is Compound B (naltrexone).
15. The method of claim 6 , wherein the compound is administered orally.
16. The method of claim 6 , wherein the compound is administered parenterally.
17. A method as claimed in claim 6 wherein said compound is administered in a daily dose of from 1 mg to 100 mg.
18. The method of claim 7 , wherein the compound of Formula (I) has one of the following structures:
19. The method of claim 7 , wherein the compound of Formula (I) has one of the following structures:
20. A method as claimed in claim 7 , wherein said compound is Compound A (nalmefene).
21. A method as claimed in claim 7 , wherein said compound is Compound B (naltrexone).
22. The method of claim 7 , wherein the compound is administered orally.
23. The method of claim 7 , wherein the compound is administered parenterally.
24. A method as claimed in claim 7 wherein said compound is administered in a daily dose of from 1 mg to 100 mg.